Marker: Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

 

Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete response six months after MT-601 treatment

https://www.globenewswire.com/news-release/2023/12/11/2793733/0/en/Marker-Therapeutics-Announces-Sustained-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-following-CAR-T-Relapse.html